Step-by-Step LC-MS/MS Workflow for Immunopeptidomics Analysis
- Tumor-associated antigens (TAAs)
- Tumor-specific neoantigens (neoantigens)
- Pathogen-derived antigens (e.g., viral and bacterial)
- Self-antigens (associated with autoimmune disease)
- Applying dynamic exclusion to reduce redundant sequencing
- Using longer chromatographic gradients to enhance separation
- Increasing AGC targets and MS resolution to improve sensitivity
- Personalized tumor vaccine design: identifying patient-specific neoantigens to improve the efficiency of T-cell activation
- TCR-T or CAR-T target discovery: confirming presented peptides with high specificity and strong immunogenic potential
- Viral or pathogen vaccine development: for example, prioritizing variant-specific antigens from SARS-CoV-2
- Mechanistic studies of autoimmune disease: identifying candidate self-peptides that may drive autoreactive immune responses
As immunotherapy has become a major focus for intervention research in cancer, viral infection, and autoimmune disease, our understanding of antigen presentation has continued to deepen. In this context, immunopeptidomics has emerged as a critical bridge between molecular omics and immunology. The overarching aim of this approach is to comprehensively characterize the repertoire of peptides presented by major histocompatibility complex (MHC) molecules at the cell surface, peptides that can be directly recognized by T cells and trigger immune responses. Accordingly, immunopeptidomics not only holds broad promise for the development of next-generation vaccines, but also provides a reliable basis for antigen prioritization in personalized cancer immunotherapy. Because LC-MS/MS (liquid chromatography-tandem mass spectrometry)-based immunopeptidomics enables the direct detection of MHC-presented peptides in authentic biological specimens, it is widely regarded as one of the most direct and reliable experimental routes for interrogating antigen presentation mechanisms. Here, we systematically outline an LC-MS/MS-based immunopeptidomics workflow, from sample preparation to MS measurement and data interpretation, to help researchers understand key implementation considerations and the practical value of this frontier technology.
Basic Principles and Research Targets of Immunopeptidomics
Immunopeptidomics focuses on endogenous peptides presented by MHC class I (MHC-I) or MHC class II (MHC-II) molecules. These peptides arise from intracellular protein degradation products and reflect cellular molecular states associated with transformation, infection, or stress. MHC-I predominantly presents short peptides of 8-11 amino acids derived from intracellular proteins, thereby activating CD8+ T cells, whereas MHC-II presents longer peptides (13-25 amino acids) to activate CD4+ T cells.
Key areas of interest typically include:
These peptide classes provide core evidence for the development of personalized vaccines, TCR-T therapies, and targeted therapeutic strategies.
Complete Experimental Workflow of LC-MS/MS-Based Immunopeptidomics
A principal experimental challenge in immunopeptidomics is that target peptides are present at low abundance and high complexity. Therefore, experimental design must be carefully optimized to maximize sensitivity and data quality.
1. Sample Preparation
Common sample types include cancer cell lines, patient tumor tissues, peripheral blood mononuclear cells (PBMCs), and HLA-transfected cells. Because MHC-presented peptides are scarce, immunopeptidomics often requires cell inputs on the order of hundreds of millions of cells, or an equivalent amount of tissue, to obtain immunopeptides at detectable levels.
2. Immunoprecipitation (IP) of MHC Molecules
MHC-peptide complexes are enriched by immunoprecipitation using specific antibodies (e.g., W6/32 for HLA class I), typically immobilized on magnetic beads or agarose resin. Key determinants at this step include efficient and intact lysis as well as antibody capture performance, both of which directly influence downstream peptide purity and recovery.
3. Weak-Acid Peptide Elution
MHC-bound peptides are eluted under weak-acid conditions (e.g., 0.1% trifluoroacetic acid, TFA). Because the eluate contains substantial background material, operations should be performed rapidly and at low temperature to minimize sample degradation and to preserve target peptides to the greatest extent possible.
4. Peptide Cleanup and Concentration
Eluted peptides are purified using C18 solid-phase extraction to remove salts, surfactants, and other interfering substances. When appropriate, additional high-pH reversed-phase fractionation can be performed to improve the detection probability of low-abundance peptides.
5. LC-MS/MS Analysis
Peptides are analyzed on high-resolution MS platforms (e.g., Orbitrap Exploris or Fusion Lumos instruments) using full-scan acquisition under no-enzyme (unspecific) settings. Data acquisition is most commonly performed using DDA (data-dependent acquisition), although DIA (data-independent acquisition) can also be adopted to increase coverage.
Recommended parameter considerations include:
6. Data Analysis and Antigen Selection
Data analysis typically relies on search engines that support no-enzyme (unspecific) searches (e.g., MaxQuant, PEAKS, and Byonic), with an appropriate false discovery rate threshold (FDR ≤ 1%). Identified peptides are then matched against HLA typing information from the relevant cells or tissues to confirm MHC restriction. When integrated with somatic mutation data and transcriptomic data, this workflow enables the screening of neoantigen candidates with immunogenic potential.
Application Prospects of Immunopeptidomics
By linking cellular protein degradation products to T-cell recognition, immunopeptidomics is demonstrating substantial potential across multiple research and translational settings:
With continued advances in MS instrumentation, analytical algorithms, and multi-omics integration strategies, immunopeptidomics is expected to play an increasingly central role in precision immunotherapy.
With its strong physiological relevance and forward-looking methodological value, immunopeptidomics is reshaping how we understand antigen recognition and immune responses. LC-MS/MS-based direct peptide identification has become an important enabling platform for neoantigen discovery and the development of personalized immunotherapies. Looking ahead, improvements in sample processing throughput and algorithmic accuracy are expected to further expand the impact of immunopeptidomics in precision medicine. For customized immunopeptidomics study strategies, MtoZ Biolabs can provide technical consultation and solution support.
MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider.
Related Services
How to order?
